Dongsung Pharm (002210) - Total Assets
Based on the latest financial reports, Dongsung Pharm (002210) holds total assets worth ₩147.95 Billion KRW (≈ $100.26 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Dongsung Pharm book value and equity for net asset value and shareholders' equity analysis.
Dongsung Pharm - Total Assets Trend (2008–2024)
This chart illustrates how Dongsung Pharm's total assets have evolved over time, based on quarterly financial data.
Dongsung Pharm - Asset Composition Analysis
Current Asset Composition (December 2024)
Dongsung Pharm's total assets of ₩147.95 Billion consist of 44.9% current assets and 55.1% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 2.1% |
| Accounts Receivable | ₩28.81 Billion | 19.0% |
| Inventory | ₩22.74 Billion | 15.0% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩666.50 Million | 0.4% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2008–2024)
This chart illustrates how Dongsung Pharm's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Dongsung Pharm market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Dongsung Pharm's current assets represent 44.9% of total assets in 2024, a decrease from 58.3% in 2008.
- Cash Position: Cash and equivalents constituted 2.1% of total assets in 2024, down from 4.2% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2008.
- Asset Diversification: The largest asset category is accounts receivable at 19.0% of total assets.
Dongsung Pharm Competitors by Total Assets
Key competitors of Dongsung Pharm based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Dongsung Pharm - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.67 | 0.98 | 1.50 |
| Quick Ratio | 0.43 | 0.68 | 1.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩-29.45 Billion | ₩-1.77 Billion | ₩25.13 Billion |
Dongsung Pharm - Advanced Valuation Insights
This section examines the relationship between Dongsung Pharm's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.59 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 32.1% |
| Total Assets | ₩151.91 Billion |
| Market Capitalization | $16.09 Million USD |
Valuation Analysis
Below Book Valuation: The market values Dongsung Pharm's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Dongsung Pharm's assets grew by 32.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Dongsung Pharm (2008–2024)
The table below shows the annual total assets of Dongsung Pharm from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩151.91 Billion ≈ $102.95 Million |
+32.13% |
| 2023-12-31 | ₩114.97 Billion ≈ $77.92 Million |
+6.75% |
| 2022-12-31 | ₩107.70 Billion ≈ $72.99 Million |
+2.98% |
| 2021-12-31 | ₩104.58 Billion ≈ $70.87 Million |
-16.81% |
| 2020-12-31 | ₩125.72 Billion ≈ $85.20 Million |
-4.56% |
| 2019-12-31 | ₩131.73 Billion ≈ $89.27 Million |
-6.04% |
| 2018-12-31 | ₩140.20 Billion ≈ $95.01 Million |
+12.89% |
| 2017-12-31 | ₩124.18 Billion ≈ $84.16 Million |
-0.96% |
| 2016-12-31 | ₩125.39 Billion ≈ $84.97 Million |
+0.65% |
| 2011-12-31 | ₩124.58 Billion ≈ $84.42 Million |
-2.53% |
| 2010-12-31 | ₩127.81 Billion ≈ $86.61 Million |
-0.08% |
| 2009-12-31 | ₩127.91 Billion ≈ $86.68 Million |
+2.68% |
| 2008-12-31 | ₩124.57 Billion ≈ $84.42 Million |
-- |
About Dongsung Pharm
Dong Sung Bio Pharm.Co.,Ltd. manufactures and sells pharmaceuticals and cosmetics in South Korea. The company offers over the counter drugs, such as emollient, vitamin supplement, alopecia treatment, antihistamines, liver disease treatment, fire extinguisher solvent, antiviral, eye drops, menopause treatment, sleep inducer, antipyretic, analgesic, anti-inflammatory, vascular reinforcement, broad-… Read more